Impact of Diabetes Mellitus Medications in Some Biomarkers of COVID-19 Infected Patients

Authors

  • Mona N. Al-Terehi College of Science, Babylon University, Hillah, Iraq
  • Mohammed A. Jawad Al-Nisour University College, Baghdad, Iraq
  • Abed J. Kadhim Al-Nisour University College, Baghdad, Iraq
  • Ahmed S. Abed Department of Medical Physics, Hilla University College, Babylon, Iraq

Abstract

COVID-19 pandemic has been the source of most health problems in the last two years with high mortality rates and fluctuation recovery rates, recorded in different countries. The diabetes mellitus (DM) is one of the multifactorial diseases that may be affected in the COVID-19 infected people. Present research was suggested to study the DM medications in some Biomarkers of COVID-19 infected patients. D-dimer and C-reactive protein (CRP) was used in the present work; the output of the distribution study subjects, according to DM patients shows there was 73% of infected COVID-19 is suffered from diabetes mellitus, and 27% was non-diabetes patients, the D-dimer levels were elevation in DM insignificant differences (p<0.004). The CRP level was found in non-significant elevation in DM (p<0.203). The DM patients enrolled in the present study were treated with three types of medications, metformin+ insulin, and insulin only. We found that in a group treated with insulin only have higher levels of d-dimer and lower levels in the group treated with metformin while the group that used both drugs, shows a high level but is lower than the group that used insulin only were significant (p 0.012). The CRP shows low levels in the group that used metformin only than others in non-significant differences (p 0.037). Also, our analysis of the relation between PCR results and DM-infected patients found that the positive results were high in the DM patients than non-DM patients in significant differences (Od 0.1037 CI95% 0.0116 to 0.9272 P 0.042). It can be concluded from finding that there was a strong association between DM and d-dimer, CRP, and these markers association with types of DM medications, and the DM cases should be careful to avoid COVID-19 infection, and the infection cases must be under hospital care.

Keywords:

Biomarkers, COVID-19, CRP, D-dimer, Diabetes mellitus, Medications

References

1. Poutanen SM. Etiologic agents of infectious diseases. In: Long SS, editor. Principles and practice of paediatric infectious diseases. 4th ed. 2012. p. 1547-1712.

2. Bogoch A, Watts A, Thomas-Bachli C, Huber MUG, Kraemer K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Trav Med. 2020;10:1093.

3. Hossain M K, Hassanzadeganroudsari M, Apostolopoulos.The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. Expert review of vaccines, 2021;1-4. Advance online publication. https://doi.org/10.1080/14760584.2 021.1915140.

4. World Health Organisation [Online]. Diabetes Available from: https://www.who.int/health-topics/diabetes [Accessed 2020 May 30].

5. Badawi A, Ryoo SG. Prevalence of diabetes in the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus: a systematic review and meta-analysis. J Public Health Res. 2016;5(3):733-739.

6. Muniyappa R, Gubbi S. COVID-19 pandemic, corona viruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736-E741.

7. Ardigo D, Valtuena S, Zavaroni I, Baroni MC, Delsignor R. Pulmonary complications of diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy. 2004;3(4):455-458.

8. Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metab Res Rev. 2019;35(6):e3159.

9. Samuel S M, Varghese E, Büsselberg D, Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role, Trends in Microbiology, 2021, In Press.

10. Al-Terehi M N, Hasan RN, AL Jboory M J. An In Silico Antisense Rna Molecules Prediction For Sars-Cov 2 Spike Protein Inhibition, PJAEE, 2020;17(7).

11. Al-Terehi MN, Alkaim AF, Yaro A. An in silico approach to design potential siRNA molecule of SARS-CoV-2 virus structural genes, a preliminary opinion for COVID-19 inhibition, Ann Trop Med & Public Health; 2020; 23(S11): SP23111.

12. A. Remuzzi, G. Remuzzi COVID-19 and Italy: what next? Lancet Lond. Engl.2020; 395 (10231),1225-1228,11.

13. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;31:e3319.

14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 28;395(10229):1054-1062.

15. Sestan M, Marinovi S, Kavazovi I, Cekinovi D, Wueest S, Turk W, Brizi I, Jonji S, Konrad D, Wensveen FM, Poli B. Virus-induced interferon-y causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49:164-177.e6.

16. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 2020;20:389-391. doi: 10.1038/s41577-020-0343-0.

17. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, Penninger JM. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 18;133(2):235-249.

18. Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the B-Cell-Centric Classification Schema. Diabetes Care. 2016 Feb;39(2): 179-186.

19. Al-Jbouri, AMS., Abood, FM, Hindi, NKK, Alkaim, AF; Evaluation of antimicrobial activity of the aquatic extract against bacterial isolates from periodontitis in Babylon Province, Iraq; Biochemical and Cellular Archives, (2018) 18; 1345-1350.

20. Kadhim, MM, Kubba, RM. Theoretical investigation on reaction pathway, biological activity, toxicity and NLO properties of diclofenac drug and its ionic carriers. Iraqi Journal of Science, 2020;61(5):936-951.

21. Al-Duhaidahawi, DL, Jabir, MS, Al-Amiery, AA, Moneim, AEA, Alkaim, AF, Kadhum, AAH; Novel antioxidants compounds derived from isatine Biochemical and Cellular Archives, (2018)18 (1); 709-713.

22. Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes Diabetes Res. Clin. Pract. 2020; 164.

23. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin JJ, Chen Z, Deng KQ, Lin L, Chen MM, Song X, Xia M, Huang X, Liu W, Cai J, Zhang XJ, Zhou F, Zhang P, Wang Y, Ma X, Xu Q, Yang J, Ye P, Mao W, Huang X, Xia J, Zhang BH, Guo J, Zhu L, Lu Z, Yuan Y, Wei X, She ZG, Ji YX, Li H. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 6;32(4):537-547.e3.

24. Agarwal S, Schechter C, Southern W, Crandall JP, Tomer Y. Preadmission Diabetes-Specific Risk Factors for Mortality in Hospitalized Patients With Diabetes and Coronavirus Disease 2019. Diabetes Care. 2020;43(10):2339-2344.

25. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399-1407.

Published

2021-08-17
Statistics
Abstract Display: 0
PDF Downloads: 0

Issue

Vol. 12 No. 3 (2021): Volume 12,Issue3

Section

Articles